The use of constitutively active GPCRs in drug discovery and functional genomics.
The complete sequencing of the human genome has afforded researchers the opportunity to identify novel G-protein-coupled receptors (GPCRs) that are expressed in human tissues. The successful identification of hundreds of GPCRs represents the single greatest opportunity for novel drug development today. However, the lack of identified ligands for these GPCRs has limited their utility for traditional drug discovery approaches that focus on ligand-based assay methods to discover and pharmacologically characterize drug candidates. Here, we review the use of constitutively activated GPCRs in the discovery pathway, both as a means to overcome the limitations of traditional drug discovery at novel GPCRs and as a tool to investigate the functionality of these receptors.
Chalmers
Derek T
DT
Arena Pharmaceuticals, 6166 Nancy Ridge Drive, San Diego, California 92121, USA. dchalmers@arenapharm.com
Behan
Dominic P
DP
D000818:Animals; D019204:GTP-Binding Proteins / Q000737:chemistry / Q000145:classification / Q000235:genetics / Q000502:physiology*; D023281:Genomics / Q000379:methods*; D006801:Humans; D011956:Receptors, Cell Surface / Q000737:chemistry / Q000145:classification / Q000235:genetics / Q000502:physiology*; D013678:Technology, Pharmaceutical / Q000379:methods*
D011956:Receptors, Cell Surface; D019204:GTP-Binding Proteins